Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck to Allow 5 India Generics Manufacturers to Make Covid-19 Treatment

04/27/2021 | 05:15am EDT

By Chris Wack

Merck & Co. said it has entered into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generics manufacturers.

Merck's molnupiravir is an investigational oral antiviral agent being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed Covid-19. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics.

Merck has entered into these agreements to speed up availability of molnupiravir in India and in other low- and middle-income countries following approvals or emergency authorization by local regulatory agencies.

The agreements have been signed with Cipla Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Hetero Labs Ltd. and Sun Pharmaceutical Industries Ltd., five generics manufacturers with World Health Organization pre-qualified manufacturing facilities and experience as major drug suppliers.

Under the agreements, Merck will provide licenses to these manufacturers to supply molnupiravir to India and more than 100 low- and middle-income countries. Merck is also in discussions with the Medicines Patent Pool to explore the potential for additional licenses.

Merck said it would also donate more than $5 million worth of oxygen-production equipment, masks, hand sanitizer and financial aid to support relief efforts in India.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

04-27-21 0715ET

Stocks mentioned in the article
ChangeLast1st jan.
CIPLA LIMITED 0.98% 937.35 Delayed Quote.13.20%
DJ INDUSTRIAL 0.80% 35116.4 Delayed Quote.14.14%
DR. REDDY'S LABORATORIES LIMITED 0.41% 4721.2 End-of-day quote.-9.28%
MERCK & CO., INC. 0.30% 76.41 Delayed Quote.-6.59%
SUN PHARMACEUTICAL INDUSTRIES LTD. -0.84% 787.8 Delayed Quote.34.18%
All news about MERCK & CO., INC.
07/30MERCK : Goldman Sachs Adjusts Price Target for Merck to $104 From $102, Maintain..
07/30MERCK : SVB Leerink Adjusts Price Target on Merck & Company to $101 From $99, Ma..
07/29SECTOR UPDATE : Health Care Stocks Closing Slightly Higher
07/29SECTOR UPDATE : Health Care Stocks Inching Higher This Afternoon
07/29MERCK : weighed down by charges in Q2, but drug sales rebound
07/29MERCK : Announces Appointment of Cristal N. Downing as Chief Communications & Pu..
07/29Merck & Co., Inc. Announces Appointment of Cristal N. Downing as Chief Commun..
07/29MERCK : Reports Higher Second-Quarter Results But Mixed Against Street Views, Na..
07/29SECTOR UPDATE : Health Care Stocks Cautiously Up Ahead of Thursday's Opening Bel..
07/29Today on Wall Street: GDP growth misses estimates
More news
Financials (USD)
Sales 2021 46 932 M - -
Net income 2021 12 744 M - -
Net Debt 2021 12 127 M - -
P/E ratio 2021 17,3x
Yield 2021 3,37%
Capitalization 193 B 193 B -
EV / Sales 2021 4,38x
EV / Sales 2022 3,98x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 76,41 $
Average target price 94,45 $
Spread / Average Target 23,6%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-6.59%193 475
JOHNSON & JOHNSON10.81%453 498
ROCHE HOLDING AG13.88%339 298
PFIZER, INC.24.10%246 075
NOVARTIS AG0.14%225 528